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Abstract
 
Plasmacytoid dendritic cells (PDCs) are a unique leukocyte population capable of secreting
high levels of type I interferon (IFN) in response to viruses and bacterial stimuli. In vitro exper-
iments have shown that upon maturation, human and murine PDCs develop into potent
immunostimulatory cells; however, their ability to prime an immune response in vivo remains
to be addressed. We report that CpG-matured murine PDCs are capable of eliciting in naive
mice antigen-specific CTLs against endogenous antigens as well as exogenous peptides, but not
against an exogenous antigen. Type I IFN is not required for priming, as injection of CpG-
matured PDCs into type I IFN receptor–deficient mice elicits functional CTL responses.
Mature PDCs prime CTLs that secrete IFN-
 
 
 
 and protect mice from a tumor challenge. In
contrast, immature PDCs are unable to prime antigen-specific CTLs. However, mice injected
with immature PDCs are fully responsive to secondary antigenic challenges, suggesting that
PDCs have not induced long-lasting tolerance via anergic or regulatory T cells. Our results
underline the heterogeneity and plasticity of different antigen-presenting cells, and reveal an
important role of mature PDCs in priming CD8 responses to endogenous antigens, in addition
to their previously reported ability to modulate antiviral responses via type I IFN.
Key words: PDC • T cell priming • type I IFN • H-Y • tetramers
 
Introduction
 
DCs play a pivotal role in the control of innate and adaptive
immune responses (1). They consist of a heterogeneous cell
population, classified into distinct subsets according to surface
phenotype, functional properties, and localization (2). In
humans, an immature DC subset with plasmacytoid mor-
phology (plasmacytoid DC [PDC]) represents a unique
leukocyte population capable of secreting high levels of
type I IFN in response to viruses and bacterial stimuli (3, 4). It
has been shown recently that human PDCs behave as bona
fide DCs, as they efficiently prime naive antigen-specific
CD8 T cells (5), and are capable of restimulating CD4 and
CD8 responses upon influenza virus infection (6). In both
experimental systems, CD4 and CD8 T cells expanded by
PDCs were capable of IFN-
 
 
 
 secretion. However, other
investigators have shown that PDCs can differentiate allo-
geneic CD8 regulatory cells and Th2 responses (4, 7),
suggesting that PDCs may have a certain degree of plasticity
in their ability to prime T cell responses.
Murine PDCs have been identified recently on the basis
of high type I IFN secretion and their unique surface pheno-
type (CD11c
 
dull
 
, B220
 
 
 
, CD11b
 
 
 
, and Gr-1
 
 
 
; references
8–10). To date, all functional studies on murine PDCs have
been performed in vitro using PDCs either isolated from
spleen or differentiated from bone marrow precursors. It
has been shown that freshly isolated murine PDCs express
lower levels of MHC and costimulatory molecules than the
myeloid CD11c
 
high
 
 CD11b
 
 
 
 subset (myeloid DC [MDC]),
possibly accounting for their reported poor stimulatory
capacity for allogeneic and naive T cells (8–11). In contrast,
PDCs matured with viral or CpG stimulation are potent
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APCs, capable of stimulating proliferation of allogeneic T
cells and naive transgenic CD4 and CD8 T cells (8, 10, 12–
14). Depending on antigen dose and Toll-like receptor en-
gagement, murine PDCs show flexibility in their T cell po-
larizing capacity, generally eliciting Th1 responses at high
and Th2 responses at low antigen doses (15). In addition,
immature PDCs have been shown to differentiate T regu-
latory cells, capable of suppressing antigen-specific T cell
proliferation (13, 16, 17).
Although in vitro experiments indicate that mature PDCs
are potent immunostimulatory cells, it remains unclear
whether they can prime antigen-specific immune responses
in vivo in naive nontransgenic animals. To address this
question, we set up an in vivo priming model in which we
monitored ex vivo by tetramer analysis the proliferation of
antigen-specific T cells after injection of PDCs either freshly
isolated from the spleen or from FLT3 ligand (FLT3-L)–
supplemented murine bone marrow cultures (18). We re-
port that CpG-matured PDCs prime CTLs specific for en-
dogenous but not exogenous antigens. CTLs primed by
PDCs acquire potent in vivo cytolytic activity, are capable
of IFN-
 
 
 
 secretion upon peptide stimulation, and protect
mice from a subsequent tumor challenge. Priming is depen-
dent on direct presentation of the antigen by the injected
DCs and does not require responsiveness to type I IFN.
Conversely, immature PDCs do not induce proliferation of
antigen-specific CTLs in vivo. However, in contrast to
what was observed in vitro, administration of immature
PDCs does not prevent responses to subsequent challenges
with viruses or DCs expressing the relevant antigen.
 
Materials and Methods
 
Mice.
 
C57BL/6, TAP-1
 
 
 
/
 
 
 
 (on C57BL/6 background),
129A (lacking type I IFN receptor; reference 19), and 129 S1/
SvEv mice were maintained at the John Radcliffe Hospital Bio-
medical Services and used at 7–12 wk of age according to institu-
tional guidelines.
 
Peptides and Tetramers.
 
UTY
 
246–254
 
 (WMHHNMDLI),
SMCY
 
738–746
 
 (KCSRNRQYL), LCMV-gp
 
34–41
 
 (AVYNFATC),
OVA
 
323–339
 
 (ISQAVHAAHAEINEAGR), and OVA
 
257–264
 
 (SI-
INFEKL) peptides were purchased from Sigma-Aldrich and
were HPLC purified. UTY
 
246–254
 
-H-2-D
 
b
 
, SMCY
 
738–746
 
-H-2-D
 
b
 
,
OVA
 
257–264
 
-H-2-K
 
b
 
, and LCMV gp
 
34–41
 
-H-2-K
 
b
 
 fluorescent tet-
rameric complexes (tetramers) were synthesized as described pre-
viously (20). The LCMV gp
 
34–41
 
-H-2-K
 
b
 
 tetramer was used in-
stead of the LCMV gp
 
33–41
 
-H-2-D
 
b
 
 tetramer (21) because, upon
priming by LCMV gp
 
33–41
 
-peptide-pulsed DCs, responses to the
octamer were dominant over those to the nonamer (unpublished
data). Tetramers were validated by staining mice primed by vac-
cinia viruses encoding the relevant protein. Background levels of
staining (
 
 
 
0.02% of total CTLs) were determined in naive mice.
 
Generation of Bone Marrow–derived DCs.
 
Culture medium was
RPMI 1640 supplemented with 2 mM 
 
l
 
-glutamine, 1% nonessen-
tial amino acids, 1% pyruvate, 50 
 
 
 
g/ml kanamycin, 0.05 mM
2-mercaptoethanol (GIBCO BRL), and 10% FCS (Hyclone). Bone
marrow cells were isolated by flushing femurs and tibia with com-
plete medium. RBCs were lysed with RBC lysis solution (Pure-
gene; Gentra Systems). The recovered cells were plated in culture
medium containing 100 ng/ml FLT3-L (R&D Systems) at 10
 
6
 
cells/ml in six-well plates in a volume of 5 ml as described previ-
ously (18). Every 3–4 d, 2.5 ml of medium was replaced with fresh
medium and FLT3-L. At day 10, half of the cultures were matured
with 5 
 
 
 
g/ml phosphorothioate CpG DNA 1826 (Coley Pharma-
ceutical). In some experiments, bone marrow cultures were incu-
bated with 500 
 
 
 
g/ml of soluble ovalbumin (fraction VII; Sigma-
Aldrich) for 20 h before sorting (CpG was added to part of the
cultures 4 h after ovalbumin). At day 11, the cultures were pheno-
typed by FACS
 
®
 
 analysis with the following mAbs: CD11b-FITC,
B220-PE, and CD19-APC (all obtained from BD Biosciences).
PDCs (CD11b
 
 
 
B220
 
 
 
CD19
 
 
 
) and MDCs (CD11b
 
 
 
B220
 
 
 
CD19
 
 
 
) were isolated by a combination of magnetic (MACS;
Miltenyi Biotec) and cell sorting (Moflo; DakoCytomation). The
purity was always 
 
 
 
97%, and CD11b
 
 
 
 cells were not detected
upon reanalysis of PDC preparations.
 
Isolation of Splenic DCs.
 
C57BL/6 males were injected i.v.
with 200 
 
 
 
g CpG DNA 1826. 16 h later, splenic DCs were en-
riched by magnetic sorting using CD11c beads (MACS; Miltenyi
Biotec) after collagenase treatment of disrupted spleens. MDCs
(CD11c
 
 
 
B220
 
 
 
Ly-6G/C
 
 
 
) and PDCs (CD11c
 
 
 
B220
 
 
 
Ly-6G/
C
 
 
 
) were subsequently purified by cell sorting (Moflo; DakoCy-
tomation) as described previously (11, 15).
 
Immunization Protocols.
 
Sorted cells were left unpulsed or
pulsed with 1 
 
 
 
g/ml of peptide in serum-free medium for 2 h at
37
 
 
 
C, extensively washed, and diluted in PBS. 200 
 
 
 
l of cells was
injected into the lateral tail vein. Animals were boosted by i.v. in-
jection of 3 
 
 
 
 10
 
5
 
 BM-DCs or 10
 
6
 
 PFUs of UV-inactivated re-
combinant vaccinia encoding the UTY
 
246–254
 
 or SMCY
 
738–746
 
minigenes or the full length ovalbumin protein (22).
 
Generation of Recombinant Vaccinia Viruses.
 
Recombinant
vaccinia viruses (WR strains) encoding the UTY
 
246–254
 
 and
SMCY
 
738–746
 
 minigenes were made by cloning each insert into
the thymidine kinase gene using the vector pSC11 as described
previously (23).
 
Isolation of PBLs and Tetramer Staining.
 
Blood was taken from
the tail vein, and PBLs were isolated after depletion of RBCs
with RBC lysis solution (Puregene; Gentra Systems). Cells were
resuspended in 25 
 
 
 
l of complete medium and incubated with
0.5 
 
 
 
g of tetramer for 25 min at 37
 
 
 
C. Cells were washed and in-
cubated with rat anti–mouse CD8
 
 
 
 (BD Biosciences) for 20 min
at 4
 
 
 
C. Cells were washed twice and analyzed using a FACSCali-
bur™ with CELLQuest™ software.
 
In Vivo Killing Assay.
 
To assess cytotoxicity, immunized and
control mice were injected with a mixture of four differentially
labeled syngeneic splenocyte populations, loaded or not with 10
 
 
 
g/ml UTY
 
246–254
 
 peptide; three populations were labeled with
different concentrations of carboxyfluorescein succinimidyl ester
(CFSE; Molecular Probes) and one with 10 
 
 
 
M of the dye
5-(and 6)-([{4-chloromethyl}benzoyl]amino) tetramethylrhoda-
mine (Molecular Probes; references 24, 25). Labeled cells were
pooled and injected at 10
 
7
 
 cells/mouse into the tail vein. Cyto-
toxicity was assessed by FACS
 
®
 
 analysis on blood taken from the
lateral tail vein at different time points. The mean percentage lysis
of peptide-loaded target cells was calculated relative to antigen-
negative controls with the following formula: 100 
 
 
 
 (100 
 
 
 
 ad-
justed percent survival). Adjusted percent survival was calculated
as follows: (percent survival Ag
 
 
 
/percent survival Ag
 
 
 
)/mean
percent survival in control animals.
 
ELISPOT.
 
Blood was taken from the tail vein, and PBLs
were isolated after depletion of RBCs with RBC lysis solution
(Puregene; Gentra Systems). In some experiments, RBC-
depleted splenocytes were used as responders. Analysis of IFN-
 
 
 
production in response to stimulation with 10 
 
 
 
M peptide for 16 h 
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was performed on MultiScreen-IP high protein–binding 96-well
plates (Millipore) using MabTech mouse IFN-
 
 
 
 ELISPOT kit
according to the manufacturer’s instructions. In all experiments,
stimulation with 1 
 
 
 
g/ml PHA served as positive control.
 
Tumor Immunity Assay.
 
10 d after priming, mice were chal-
lenged with subcutaneous injection of 10
 
6
 
 B16-F10 tumor cells
expressing the LCMV gp
 
33–41
 
 minigene (26). Mice were moni-
tored for tumor growth every 3–4 d, and the tumor size for each
group was calculated as the mean of the products of bisecting di-
ameters (
 
 
 
 SEM). Measurements were terminated for each group
when the first animal developed ascitis, when the tumor became
ulcerated, or when it grew in excess of 200 mm
 
2
 
.
 
Intracellular Cytokine Staining.
 
Spleens were harvested 8–9 d
after priming, and lymphocytes were isolated after depletion of
RBCs with RBC lysis solution (Puregene; Gentra Systems). Cells
were plated in complete medium and stimulated with 10 
 
 
 
g/ml
UTY
 
246–254
 
 peptide, 10
 
 
 
6
 
 M PMA (Sigma-Aldrich), and 1 
 
 
 
g/ml
ionomycin (Sigma-Aldrich) or left unstimulated. 5 
 
 
 
g/ml Brefel-
din A (Sigma-Aldrich) was added after 1 h, and cells were col-
lected after a total of 6 h. Cells were fixed in 2% paraformalde-
hyde, permeabilized in saponin buffer (27), and stained with
antibodies to mouse IFN-
 
 
 
–FITC, IL-2–PE, IL-10–PE, and IL-
4–APC (BD Biosciences). Tetramer staining was performed on a
sample of unstimulated splenocytes as described in previous para-
graphs for blood PBLs.
 
Online Supplemental Material.
 
Fig. S1 shows the phenotype of
immature and CpG-matured PDCs and MDCs isolated from
FLT3-L–supplemented bone marrow cultures. Fig. S2 supplements
Fig. 1 and shows priming of SMCY
 
738–746
 
-specific CTLs by CpG-
matured PDCs. Fig. S3 shows the phenotype of immature and
CpG-matured PDCs differentiated from type I IFN receptor–defi-
cient mice (129A) and wild-type 129 S1 mice. Fig. S4 supplements
Fig. 10 and shows priming of OVA
 
257–264
 
-specific CTLs by pep-
tide-pulsed mature PDCs. Online supplemental material is available
at http://www.jem.org/cgi/content/full/jem.20031059/DC1.
 
Results
 
Intravenous Injection of CpG-matured Male PDCs Induces
Functional CTL Responses.
 
Thus far, the stimulatory ca-
pacity of murine PDCs has been investigated only in vitro
against transgenic T cells (8, 10, 12–14). Therefore, we de-
veloped an in vivo model to study the ability of PDCs to
prime and polarize antigen-specific T cells from naive non-
transgenic precursors. We differentiated both PDCs and
control MDCs from murine bone marrow cultures supple-
mented with FLT3-L (18) and isolated the two DC popu-
lations by a combination of magnetic and cell sorting. In
preliminary experiments, we observed that MDCs isolated
from FLT3-L or GM-CSF 
 
 
 
 IL-4–supplemented cultures
elicited qualitatively and quantitatively comparable CTL
responses (unpublished data) and, therefore, restricted our
subsequent analysis to FLT3-L–differentiated MDCs. The
phenotype of bone marrow–derived PDCs and MDCs is
shown in Fig. S1 (available at http://www.jem.org/cgi/
content/full/jem.20031059/DC1).
In a first set of experiments, we investigated the response
to an endogenous antigen, the male-specific transplantation
antigen H-Y. When injected with male cells, female mice of
the H-2
 
b
 
 haplotype develop an immunodominant H-2-D
 
b
 
–
restricted response against the UTY
 
246–254
 
 peptide (WMHH-
NMDLI) that can be monitored by tetramer analysis (28, 29).
UTY
 
246–254
 
-specific CTL responses were monitored ex
vivo in the blood of female C57BL/6 mice injected with
male PDCs or MDCs, either immature or CpG matured.
Mature PDCs were as efficient as mature MDCs in eliciting
UTY
 
246–254
 
-specific CTLs, as detected by tetramers (Fig. 1
A). In contrast, although immature MDCs always elicited a
distinct CTL population (although lower in numbers as
compared with mature MDCs), immature PDCs never in-
duced proliferation of UTY
 
246–254
 
-specific CTLs above the
detection limit of the tetramer staining (Fig. 1 A). Similar
results were obtained when responses to the subdominant
H-2-D
 
b
 
–restricted SMCY
 
738–746
 
 epitope (28) were moni-
tored (unpublished data; Fig. S2, available at http://
www.jem.org/cgi/content/full/jem.20031059/DC1).
To better evaluate quantitatively the CTL responses, we
titrated the numbers of DCs. At low numbers (3,000 cells/
mouse), MDCs were far more efficient than PDCs in elic-
iting UTY
 
246–254
 
-specific CTLs (Fig. 1 B), whereas at
10,000 cells/mouse, PDCs and MDCs elicited a similar
Figure 1. Intravenous injec-
tion of CpG-matured male
PDCs induces CTL responses.
(A) C57BL/6 mice (n   5) were
injected i.v. with 105 male
MDC or PDCs, immature or
CpG matured. Control animals
were injected with female
MDC. CTL responses were as-
sessed in the blood by ex vivo
FACS® analysis using UTY246–254-
H-2-Db tetramers 7 d after
priming. Mean proportions of
tetramer  cells as a percentage of
CD8 cells (  SEM) for each
group are shown. (B) C57BL/6
mice (n   5) were injected with
graded numbers of male CpG-
matured MDC (gray bars) or PDCs (black bars) and boosted after 1 wk with UV-inactivated vaccinia-UTY246–254 minigene. CTL responses were assessed in
the blood by ex vivo tetramer staining 8 d after boosting. Tetramer stainings of control mice, primed by female MDC or by vaccinia-UTY246–254
minigene alone, are shown (white bars).In Vivo Priming by Murine PDCs 570
UTY246–254-specific CTL response. However, responses
were weaker than in mice immunized with 105 cells (Fig. 1
A) and were detected only upon in vivo restimulation with
vaccinia virus encoding the UTY246–254 minigene.
The functional state of the induced UTY246–254-specific
CTLs was investigated by assessing their cytotoxic capacity
and cytokine secretion upon antigen exposure. Cytotoxicity
was assayed in vivo against syngeneic splenocyte targets, ei-
ther male or peptide-pulsed female that had been labeled
with a fluorescent dye and injected into the lateral vein 10 d
after priming. Specific lysis of the antigen-expressing cells
was determined against control female splenocytes not
pulsed with the UTY246–254 peptide. UTY246–254-specific
CTLs primed by mature PDCs efficiently lysed pulsed with
10  g/ml of peptide female cells, as well as unpulsed male
splenocytes (Fig. 2, B and C). Lysis of unpulsed male sple-
nocytes, expressing a much lower density of UTY246–254–Db
complexes than UTY246–254 peptide-pulsed cells, is indica-
tive of expansion of high affinity CTLs. The majority of
peptide-pulsed female targets were lysed within the first
17 h, whereas lysis of unpulsed male cells continued over
the next 96 h, consistent with UTY246–254–Db complexes
being presented at lower density but continuously over time
(Fig. 2 B; not depicted). The cytolytic activity detected in
mice primed by immature and mature MDCs correlated
with the extent of CTL priming. No specific lysis above
background was observed in mice primed by immature
PDCs, mirroring the lack of detectable CTLs in the blood.
ELISPOT assays were performed to assess the capacity of
UTY246–254-specific CTLs to secrete IFN-  in response to
peptide stimulation. As shown in Fig. 3, and in agreement
with the tetramer data, mice primed by either mature
PDCs or immature and mature MDCs were capable of rec-
ognizing the UTY246–254 peptide in an ex vivo assay, with-
out further in vitro restimulation. No specific IFN-  secre-
tion was observed in mice primed by immature PDCs.
Intravenous Injection of CpG-matured Male PDCs Induces
Type I Polarization of Splenic UTY246–254-specific CTLs. To
further characterize the type of polarization induced by
priming with mature PDCs, freshly isolated splenocytes
Figure 2. Intravenous injec-
tion of CpG-matured male
PDCs induces functional CTL
responses. C57BL/6 mice (n   5)
were primed as described in
Fig. 1 A. (A) CTL responses
were assessed in the blood by
ex vivo FACS® analysis using
UTY246–254-H-2-Db tetramers
7 d after priming. One repre-
sentative animal per group is
shown. (B) 10 d after priming,
cytolytic activity of the
UTY246–254-specific cells was
assessed in vivo against female
syngeneic splenocytes un-
pulsed or peptide pulsed (CFSE
labeled), male splenocytes un-
pulsed (CFSE labeled), or pep-
tide pulsed (5-(and 6)-([{4-
chloromethyl}benzoyl]amino)
tetramethylrhodamine labeled)
as summarized in the cartoon.
Correlation between tetramer
staining (A) and lysis of CFSE-
labeled target cells at 17 and
96 h (B) is shown. The mouse
primed by CpG-PDCs has a
total of 2% UTY246–254-CTL (as
a percentage of CD8 cells). (C)
Analysis of mean antigen-specific lysis 17 h after target cell injection, calculated as described in Materials and Methods. Cells used for priming are
shown on the x axis. Each panel depicts specific lysis of the labeled targets (top left).
Figure 3. Intravenous injection of CpG-matured male PDCs induces
IFN- –secreting CTL. C57BL/6 mice (n   5) were primed as described
in Fig. 1. ELISPOT assay was performed on blood PBLs to assess IFN- 
secretion by antigen-specific cells in response to 10  g/ml UTY246–254
peptide 7 d after priming. All animals showed comparable responses to
PHA stimulation (not depicted).Salio et al. 571
were stimulated in vitro with the UTY246–254 peptide or
PMA   ionomycin 8 d after priming. Analysis of intracel-
lular cytokines revealed that CD8 T cells secreted the type
1 cytokine IFN-  in response to both the specific peptide
and PMA   ionomycin (Fig. 4). IL-2 was also detected in
CD8 T cells stimulated with PMA   ionomycin. In con-
trast, CD8 cells did not secrete the type 2 cytokines IL-4
and IL-10 in response to either stimulation protocol. IL-4
and IL-10 were secreted only by the CD8 negative cells in
response to PMA   ionomycin. A similar pattern of polar-
ization was observed in mice primed by mature MDCs
(unpublished data). Although the frequencies of tetramer 
cells in the spleen and in the blood were comparable, a
higher proportion of splenic UTY246–254-specific CTLs se-
creted IFN-  in response to the specific peptide (Fig. 4;
not depicted), which may reflect homing of effector T cells
to the spleen. We conclude that mature PDCs are able to
efficiently prime antigen-specific CTLs, capable of cy-
tolytic activity and IFN-  secretion.
Priming of UTY246–254-specific CTLs by Freshly Isolated
CpG-matured Splenic PDCs. It has been shown previ-
ously that freshly isolated splenic PDCs are less mature
than their bone marrow–derived counterparts, hence they
are also less immunostimulatory (15). Preliminary experi-
ments showed that injection of immature splenic MDCs,
in contrast to bone marrow–derived MDCs, did not elicit
UTY246–254-specific CTLs detectable by ex vivo tetramer
staining (unpublished data). Therefore, we isolated splenic
PDCs and MDCs from male mice previously injected
with CpG to induce in vivo DC maturation. Both MDCs
and PDCs elicited UTY246–254-specific CTLs, although re-
sponses were much weaker than those elicited by equal
numbers of bone marrow–derived DCs and were detect-
able only upon in vivo restimulation with vaccinia virus
Figure 4. Intravenous injection of CpG-matured
male PDCs induces type I polarization of spleen
CTL. C57BL/6 mice (n   3) were injected i.v.
with 105 male CpG-matured MDC or PDCs. Sple-
nocytes from a mouse primed by CpG-matured
PDCs were in vitro restimulated with UTY246–254
peptide or PMA and ionomycin, and intracellular
cytokine accumulation was assessed as described in
Materials and Methods 8 d after priming. The tet-
ramer staining for the same sample is also shown.
One experiment representative of three is shown.
Similar profiles were obtained in mice primed by
CpG-matured male MDC, whereas naive female
C57BL/6 controls did not respond to the peptide.
Figure 5. Intravenous injec-
tion of CpG-matured male
splenic PDCs induces CTL re-
sponses. C57BL/6 mice (n   3)
were injected i.v. with 0.5   105
male splenic MDC or PDCs
(isolated from CpG-treated an-
imals) and boosted after 1 wk
with UV-inactivated vaccinia-
UTY246–254 minigene. (A) CTL
responses were assessed in the
blood by ex vivo FACS® analy-
sis using UTY246–254-H-2-Db
tetramers 8 d after boosting.
Mean proportions of tetramer 
cells as a percentage of CD8
cells (  SEM) for each group
are shown. (B) IFN-  ELISPOT was performed on splenocytes to assess responsiveness to 10  g/ml UTY246–254 peptide 9 d after boosting. All
animals showed comparable responses to PHA stimulation (not depicted).In Vivo Priming by Murine PDCs 572
encoding the UTY246–254 minigene (Fig. 5 A). UTY246–254-
specific CTLs primed by mature splenic PDCs and MDCs
were functional, as shown by IFN-  secretion in response
to the cognate peptide in an ex vivo ELISPOT assay
(Fig. 5 B).
Priming of UTY246–254-specific CTLs Relies upon Direct Pre-
sentation of the Male Antigen by the Injected DCs. Priming
of UTY246–254-specific CTLs by CpG-matured PDCs and
MDCs could be due to direct presentation of the UTY246–254
peptide by the male APCs. Alternatively, proliferation of
UTY246–254-specific CTLs could be due to uptake and pre-
sentation of male APC debris by resident female DCs, a
mechanism known as cross-priming. Indeed, cross-prim-
ing has been shown to be effective for the generation of
cytotoxic T cells, and it may be the dominant route for
priming of some responses (30, 31). In vitro experiments
showed that presentation of the UTY246–254 epitope is en-
tirely TAP-dependent as UTY246–254-specific T cells did
not recognize TAP-1–deficient male APCs (unpublished
data). Therefore, we used TAP-1–deficient male BM-DCs
as immunogens to distinguish between direct versus cross-
presentation. Injection of as many as 106 male TAP-1 / 
BM-DCs, either immature or CpG matured, failed to
prime UTY246–254-specific CTLs in female C57BL/6 mice
(Fig. 6). In contrast, control mice developed good re-
sponses after injection with 105 wild-type BM-DCs. After
boosting with vaccinia-UTY246–254 minigene, only mice
that had been primed with 106 male TAP-1 /  DC (i.e.,
10 times more APCs than used in previous experiments)
showed enhanced CTL responses (unpublished data). In
agreement with the observation that UTY246–254-specific
CTL responses cannot be efficiently generated upon prim-
ing by  -2m–deficient APCs (28), we conclude that the
role of cross-priming in generating UTY246–254-specific
CTLs in this system is marginal, and can only be appreci-
ated when animals are injected with large numbers of
APCs. Therefore, proliferation of UTY246–254-specific
CTLs in our in vivo model can be accounted for by direct
presentation of the endogenous antigen by the injected
PDCs and MDCs.
Lack of Priming by Intravenous Injection of Immature Male
PDCs Does Not Prevent Subsequent Induction of Functional
UTY246–254-specific Responses. The inability of immature
PDCs to prime antigen-specific CTLs could reflect the lack
of expression of costimulatory or adhesion molecules essen-
tial to trigger naive T cell proliferation. Alternatively, im-
mature PDCs could have induced the proliferation of aner-
gic or regulatory cells nonreactive to further antigenic
Figure 6. Direct presentation
and not cross-priming accounts for
expansion of UTY246–254-specific
CTL. C57BL/6 mice were in-
jected  i.v. with the indicated
numbers of male immature or
CpG-matured BM-DCs (gener-
ated in FLT3-L). CTL responses
were assessed in the blood by
FACS® analysis using UTY246–254-
H-2-Db tetramers 7 d after prim-
ing, and dot plot profiles for indi-
vidual mice are shown. Only the
mice injected with 106 BM-DCs
showed secondary responses after
boosting with vaccinia-UTY246–254
minigene (not depicted).Salio et al. 573
challenge or unable to bind UTY246–254-Db tetramers (32,
33). The possibility of anergy or negative regulation was
ruled out by demonstrating that mice injected previously
with immature PDCs developed cytolytic male-specific
CD8 T cells upon boosting by splenocytes (Fig. 7, A and
B). The acquisition of cytolytic activity correlated with the
appearance of tetramer  CTLs in the blood (Fig. 7 C),
which also secreted IFN-  in response to the cognate pep-
tide in an ex vivo ELISPOT assay (Fig. 7 D).
As a further assessment of functional activity, we showed
that previous injection of immature PDCs did not prevent
expansion of UTY246–254-specific CTLs 1 wk after in vivo
boosting with either male BM-DCs or vaccinia virus en-
coding the UTY246–254 minigene (Fig. 7, E and F).
We conclude that, despite the inability to detect
UTY246–254-specific CTLs after one round of injection with
immature PDCs (by either tetramer, ELISPOT, or in vivo
killing assays), there was no evidence of tolerance to subse-
quent antigenic challenge.
Type I IFN Receptor–deficient CpG-matured Male PDCs
Prime IFN-  Secreting UTY246–254-specific CTLs. PDCs are
a unique leukocyte population capable of secreting high
levels of type I IFN in response to viruses and bacterial
stimuli (8–10). Because type I IFN is important for the sur-
vival and proliferation of memory CD8 T cells (34, 35), we
investigated the priming capacity of CpG-matured PDCs
in mice lacking type I IFN receptor (129A mice) (19).
As compared with 129 wild-type mice, 129A mice had
normal numbers of PDCs ex vivo in the spleen and in vitro
after culturing bone marrow cells in the presence of FLT3-L
(unpublished data). In addition, 129A PDCs underwent
maturation after CpG treatment, although to a lower ex-
tent than their wild-type counterpart (Fig. S3, available at
http://www.jem.org/cgi/content/full/jem.20031059/DC1).
Female 129A mice injected with male CpG-matured 129A
PDCs developed antigen-specific CTLs, which could also
be boosted by UV-inactivated vaccinia UTY246–254 mini-
gene, as shown previously for C57BL/6 mice (Fig. 8 A). In
addition, UTY246–254-specific CTLs primed by mature
129A PDCs secreted IFN-  in response to the cognate
peptide in an ex vivo ELISPOT assay (Fig. 8 B). These re-
sults suggest that in the absence of viral infection, type I
IFN responsiveness is not essential for CTL priming by
CpG-matured PDCs.
Figure 7. Intravenous injection of immature male PDCs does not prevent induction of subsequent UTY246–254 responses. C57BL/6 mice (n   3) were
primed as described in Fig. 1. 10 d after priming, cytolytic activity of the UTY246–254-specific cells was assessed in vivo against female or male syngeneic
splenocytes unpulsed or peptide pulsed (as detailed in Fig. 1). The analysis of mean antigen-specific lysis 17 h (A) and 1 wk (B) after target cells injection
is shown, calculated as described in Materials and Methods. The priming conditions are specified on the x axis. The first group of mice (controls) was
injected with labeled splenocytes only and not with DC. The second group of mice was primed by female MDC, to control for responses to components
of FCS used in the BM cultures. The high numbers of splenocytes used for the in vivo killing assay primes UTY246–254-specific CTL within 7 d (28), and
this is reflected by the specific clearance of male splenocytes shown in B but absent at the earlier time point. The lack of clearance of peptide-pulsed
female splenocytes reflects the short half life of the peptide on the surface of these cells, which, therefore, represent an important internal control for the
experiment. (C) Mean proportions of tetramer  cells as a percentage of CD8 cells (  SEM) for each group 7 d after PDC priming (white bar) and 1 wk
after the in vivo killing assay (black bars). (D) IFN-  ELISPOT performed on blood PBLs to assess responsiveness to 10  g/ml UTY246–254 peptide 1 wk
after the in vivo killing assay. All animals showed comparable responses to PHA stimulation (not depicted). The same groups of animals are shown in A–D.
(E and F) Mean proportions of UTY246–254-H-2-Db tetramer  cells as a percentage of CD8 cells (  SEM) after in vivo boosting with male immature
DCs (E, staining performed at day 7) or UV-inactivated vaccinia-UTY246–254 minigene (F, staining performed at day 8).In Vivo Priming by Murine PDCs 574
Priming by CpG-matured PDCs Induces Protective CTL
Responses. We have shown that PDCs can efficiently
present an endogenous antigen and prime naive CTL pre-
cursor. We extended these results by analyzing the ability
of peptide-pulsed PDCs to prime antigen-specific CTLs.
We pulsed PDCs and MDCs with the LCMV gp34–41 pep-
tide (Kb restricted) and monitored ex vivo LCMV gp34-
specific CTLs by tetramer staining. In accordance with
what was observed previously, CpG-matured PDCs and
MDCs induced similar proliferations of LCMV gp34-CTL;
immature MDCs were somewhat intermediate, and no
priming was induced by immature PDCs (Fig. 9 A).
These animals were challenged at day 10 with B16-F10-
gp33, a derivative of the aggressive melanoma B16 that
grows rapidly when injected in C57BL/6 mice (26). As
shown in Fig. 9 B, mice that had been primed by CpG-
matured PDCs or MDCs were completely protected from
tumor growth and remained tumor free for up to 2 mo (not
depicted). Mice primed by immature MDCs succumbed to
the tumors, although they did so 2 wk later than mice in-
jected with immature PDCs (which did not develop LCMV
gp34-CTL) or unimmunized control groups.
Lack of Presentation of Exogenous Antigens by Bone Marrow–
derived PDCs. To further characterize the antigen-pro-
cessing capacity of PDCs as compared with classical MDCs,
we investigated the presentation of a model exogenous an-
tigen, soluble ovalbumin. We sorted PDCs and MDCs
from bone marrow cultures prepulsed with ovalbumin in
the presence or absence of a maturation stimulus to induce
cross-presentation (36). Ex vivo SIINFEKL-Kb tetramer
staining detected primary CTL responses only upon injec-
tion of mature MDCs (unpublished data). After boosting
with vaccinia virus encoding full-length ovalbumin, mice
primed by ovalbumin-loaded PDCs did not expand SIIN-
FEKL-specific CTLs above controls, regardless of the PDC
maturation stimulus (Fig. 10 A). In contrast, CTL responses
primed by MDCs were boosted two- to fourfold.
As a control, both CpG-matured PDCs and MDCs
pulsed with the OVA257–264 peptide elicited functional SI-
INFEKL-specific CTLs detectable in the blood by tetramer
staining (Fig. S4, available at http://www.jem.org/cgi/
Figure 8. Type I IFN receptor–deficient CpG-matured male PDCs
prime IFN- –secreting CTL. Type I IFN receptor–deficient mice (129A;
n   2) were injected i.v. with 0.6   105 CpG-matured MDC or PDCs
(also generated from 129A mice). 2 wk after priming, mice were boosted
with UV-inactivated vaccinia-UTY246–254 minigene. (A) CTL responses
were assessed in the blood by FACS® analysis using UTY246–254-H-2-Db
tetramers 9 d after priming (gray bars) or 8 d after boosting (black bars).
Tetramer stainings of control mice, naive or primed by vaccinia-UTY246–254
minigene alone, are shown as white bars (the priming conditions are specified
on the x axis). Mean proportions of tetramer  cells as a percentage of
CD8 cells (  SEM) for each group are shown. (B) IFN-  ELISPOT was
performed on blood PBLs to assess responsiveness to 10  g/ml UTY246–254
peptide 9 d after priming. All animals showed comparable responses to
PHA stimulation (not depicted).
Figure 9. Priming by CpG-matured PDCs induces protective CTL
responses. C57BL/6 mice (n   5) were primed by intravenous injection
of 2   105 immature or CpG-matured MDC or PDCs pulsed with 1  g/ml
LCMV gp34–41 peptide. Control animals were injected with unpulsed
CpG-DCs. (A) CTL responses were assessed in the blood by FACS®
analysis using LCMV gp34–41-H-2-Kb tetramers 7 d after priming. Mean
proportions of tetramer  cells as a percentage of CD8 cells (  SEM) for
each group are shown. (B) Progression of B16-F10-gp33 tumors implanted
s.c. 10 d after priming. Mean tumor sizes per group   SEM are shown.
An additional control group (n   5) that did not receive DCs was included.Salio et al. 575
content/full/jem.20031059/DC1). Mice primed by MDC
showed significant IFN-  secretion in response to ovalbu-
min class I and class II peptides, whereas the response in
mice primed by PDCs was comparable to that of control
mice infected with vaccinia-OVA only (Fig. 10 B).
Discussion
In this paper, we have shown that CpG-matured murine
PDCs efficiently prime antigen-specific CTLs in vivo from
naive nontransgenic precursors. PDC-primed CTLs display
cytolytic activity in vivo against target cells expressing the
relevant antigen and are capable of protecting mice from a
subsequent challenge with a tumor recombinant for the
immunizing peptide. CTL priming occurs after injection
of peptide-pulsed PDCs, but more importantly, we dem-
onstrated that PDCs present endogenous antigens for
which the density of MHC–peptide complexes at the cell
surface is much lower than after peptide pulsing. However,
PDCs are not able to present exogenous antigens, in con-
trast to MDCs, thus underlining the heterogeneity within
the DC populations.
Previous works showed that, upon in vitro maturation,
PDCs develop into potent immunostimulatory cells, al-
though not to the same extent as control MDCs (8, 10, 12–
14). In our in vivo experiments, mature PDCs and MDCs
injected at high numbers elicited comparable responses,
qualitatively and quantitatively, whether presenting the en-
dogenous antigen or peptide pulsed. Only when limiting
numbers of DCs were injected, MDCs were more stimula-
tory than PDCs. In line with our results, Dalod et al. (37)
showed recently that PDCs purified after in vivo challenge
with murine cytomegalovirus (MCMV) became as potent
as other DC subsets for activation of naive CD8 T cells.
Dalod et al. did not address whether PDCs could also
present endogenous viral antigens because MCMV did not
infect PDCs, but only induced their maturation. Our re-
sults showing priming of UTY246–254-specific CTL re-
sponses by male PDCs strongly suggest that PDCs, infected
by viruses inducing their maturation, would be capable of
priming virus-specific T cell responses.
In contrast with the majority of the analyses, Krug et al.
have shown that splenic PDCs failed to stimulate a strong
proliferation of naive CD4 and CD8 T cells, even after in
vivo viral stimulation, questioning whether PDCs belong
to the DC system (11). Conversely, we have shown that,
although less efficient than bone marrow–derived PDCs,
freshly isolated in vivo–matured splenic PDCs are able to
prime UTY246–254-specific CTLs. It is possible that matura-
tion induced by either CpG (our model) and MCMV (37)
or VSV (11) may not generate functionally equivalent cells
as a consequence of different Toll-like receptor engage-
ment and, therefore, account for the observed discrepan-
cies. With respect to the model antigen used, we analyzed
ex vivo CTL responses specific for the immunodominant
H-Y UTY246–254-H-2-Db epitope and the subdominant
SMCY738–746-H-2-Db epitope in nontransgenic animals. In
contrast, Krug et al. have looked at the endogenous presen-
tation of the SMCY738–746-H-2-Db epitope using TCR
transgenic mice (38). These mice fail to reject male skin
grafts, and SMCY738–746 TCR transgenic CD8 T cells do
not induce graft versus host disease when transferred in
male nude mice (39, 40), suggesting that this receptor may
have poor reactivity for its ligand. In addition, SMCY738–746
TCR transgenic CD8 T cells have a defect in cytotoxicity
in response to male targets that can be overcome at ele-
vated densities of the cognate peptide (41, 42), which may
be present on the surface of MDCs but not PDCs (11).
We have not studied the capacity of mature bone mar-
row–derived PDCs to present endogenous antigens to CD4
T cells. However, as the development of the UTY246–254-
specific CTL response is strictly dependent on T cell
help from H-Y-Ab CD4 cells (28), we speculate that ma-
Figure 10. Lack of presentation of soluble ovalbumin by bone marrow–
derived PDCs. BM cultures were pulsed on day 10 with 500  g /ml of
soluble ovalbumin in the presence or absence of CpG. MDC and PDCs
were sorted on day 11. C57BL/6 mice (n   3) were primed by intrave-
nous injection of 105 cells and boosted after 10 d with vaccinia virus encoding
full-length ovalbumin. (A) CTL responses were assessed in the blood by
FACS® analysis using SIINFEKL-H-2-Kb tetramers 7 d after boosting.
Mean proportions of tetramer  cells as a percentage of CD8 cells (  SEM)
for each group are shown. (B) IFN-  ELISPOT was performed on spleno-
cytes to assess responsiveness to ovalbumin MHC class I (SIINFEKL) and
class II–restricted peptides (each at 10  g/ml) 10 d after boosting. All animals
showed comparable responses to PHA stimulation (not depicted).In Vivo Priming by Murine PDCs 576
ture PDCs might have primed CD4 as well as CD8 male-
specific cells.
It has been shown that human immature MDCs induce
differentiation of CD4 and CD8 regulatory T cells, both in
vivo and in vitro (43, 44). In the mouse, targeting of anti-
gen in vivo to immature DCs induces CD4  CD25  regu-
latory T cells and CD8 T cell tolerance (45, 46). Upon in-
jection of immature MDCs, we elicited functional CTLs,
although in lower numbers than with mature MDCs, and
this can be explained by the fact that these cells may have
undergone a limited degree of maturation during the cul-
ture/sorting period (unpublished data). Regulatory T cells
have also been differentiated in vitro by CD40L-activated
human PDCs (7) and murine immature PDCs (13, 16, 17),
and it has been hypothesized that thymic PDCs might be
involved in Treg differentiation (13). However, in our in
vivo priming model, we did not elicit any antigen-specific
CTLs when mice were injected with immature PDCs
(male DCs or peptide pulsed), making it difficult to test for
any regulatory activity. Nevertheless, exposure to imma-
ture PDCs did not prevent induction of immunity after
subsequent challenge with DCs, recombinant virus, or
splenocytes, ruling out establishment of long-term toler-
ance. Although these results might at first seem difficult to
reconcile with published data, they may be explained by
the different experimental systems used. Indeed, previous
in vivo studies have been performed with adoptively trans-
ferred naive transgenic T cells, whereas our paper relies on
endogenous CTL precursors present in much lower num-
bers. The development of antibodies to specifically target
antigens to PDCs in vivo, as described for CD8   DCs via
DEC-205 (45, 46), will help to address whether immature
PDCs may also induce tolerance and T regulatory cells.
With respect to T cell polarization, we have shown that
CTLs primed by CpG-matured PDCs secreted mainly
IFN-  in response to the cognate antigen both by ex vivo
ELISPOT and intracellular cytokine assays. Other investiga-
tors have reported high IFN-  by transgenic CTLs polarized
in vitro by mature PDCs pulsed with OVA257–264 or LCMV
gp33–41 peptides (12, 37). A flexibility of murine PDCs in di-
recting Th1 and Th2 development of CD4 transgenic T
cells has been described, depending on antigen dose and
Toll-like receptor engagement (15). This is likely to reflect
differences in polarization of CD4 and CD8 cells, consistent
with the lack of secretion of IL-4 by PMA   ionomycin–
stimulated CD8 splenocytes (Fig. 3). We have not been able
to induce UTY246–254-specific CTL proliferation when mice
were injected with immature PDCs (male PDCs or peptide
pulsed); therefore, we cannot comment on the CTL polariz-
ing capacity of PDCs at different stages of maturation.
We have shown that, in the absence of viral infection,
type I IFN is not required for priming because injection of
CpG-matured PDCs into type I IFN receptor–deficient
mice (129A) elicits functional CTL responses. In contrast,
during a viral infection, the importance of PDC-derived
type I IFN in initiating innate immune responses and in the
cross-talk with other DC subsets for induction of adaptive
immunity has been very elegantly demonstrated (37, 47).
However, we cannot exclude the possibility that other re-
cently described members of the IFN family may play a key
role in PDC stimulatory capacity (48, 49), and some re-
dundancy in the IFN system may be envisaged. Such re-
dundancy may be implied by the observation that 129A
mice have PDCs (Fig. S3, available at http://www.
jem.org/cgi/content/full/jem.20031059/DC1) in contrast
to what was reported for IFN consensus sequence-binding
protein (a transcription factor involved in the IFN signaling
pathway)–deficient mice that lack PDCs and have a defect
in the activation of CD8   DCs (50–52). In addition,
129A PDCs mature in response to CpG treatment, al-
though to a lower extent than their wild-type counterpart,
consistent which was with what was reported previously
(53–55). This level of maturation is indeed sufficient for in
vivo priming of functional CTL responses, although in
other experimental models, amplification of DC matura-
tion by IFN signaling may be required for optimal regula-
tion of the immune response (37).
Although in vivo mature PDCs can induce proliferation
of functional CTLs specific for an endogenous antigen as
well as for exogenously loaded peptides, they are unable to
present exogenous antigens, even in the presence of matura-
tion signals known to activate cross-presentation in MDCs
(36). This observation is consistent with a recent paper
showing that PDCs were far less efficient compared with
other DC subsets in presenting s.c. injected Leishmania major
antigens (56). Lack of presentation of exogenous antigens
could be due to poor endocytic activity compared with
MDCs (unpublished data; references 57, 58), or to differ-
ences in the antigen-processing and -presenting machinery
between MDCs and PDCs, consistent with the different ex-
pression pattern of cathepsins in human MDCs and PDCs
(59). Our results underline the heterogeneity and plasticity
within the APC family, highlighted previously between
CD8   and CD8   MDCs (60–63). We envision that in
vivo PDCs may contribute to priming antigen-specific CD8
and CD4 T cell responses by efficiently presenting endoge-
nous antigens, whereas their role in priming T cell responses
to exogenous antigens would be negligible; in this respect,
differing from both CD8   and CD8   MDCs. In addi-
tion, PDCs could modulate the function of other DC sub-
sets by inducing their functional maturation and promoting
cross-presentation via type I IFN secretion (64). Finally,
these data validate in vivo our previous results on the ability
of human PDCs to prime antigen-specific naive T cells (5),
and provide a rationale for the combined use of mature
MDCs and PDCs in vaccine trials to optimize the induction
of innate and adaptive immune responses.
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